Bibliothek

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    ISSN: 1432-2307
    Schlagwort(e): Bladder neoplasm ; p53 ; erbB-2 ; Metastasis
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract Overexpression of p53 anderbB-2 was studied by immunohistochemistry in formalin-fixed tissue samples of 179 patients with transitional cell carcinoma of the urinary bladder. p53 immunostaining was strongly correlated with tumour stage (P〈0.0001). This was driven by a marked difference in p53 expression between pTa (37% positive) and pT1 (71%) tumours, while there was no difference between pT1 and pT2-4 tumours. Similarly, a strong overall association between p53 expression and grade (P〈0.0001) was driven by a marked difference between grade 1 (28%) and grade 2 tumours (71%), and there was no significant difference between grade 2 and grade 3 tumours. Surprisingly, the frequency oferbB-2 overexpression was higher in pT1 tumours (74%) than in either pTa (49%;P=0.0265) or pT2-T4 (56%;P=0.0645) tumours. Both p53 anderbB-2 expression was also associated with metastasis. Metastases were found in 77% of patients with p53 positive primary tumours, but in only 50% of the patients with p53 negative primary tumours (P=0.022). Metastases were found in 66% of patients witherbB-2 positive primaries, but in only 37% of theerbB-2 negative primaries (P=0.020). Of 32 patients with positivity for both p53 anderbB-2, 84% developed metastases, as compared to 49% of patients with positivity for either one or neither positive (P=0.002). We conclude that both p53 anderbB-2 over-expression are associated with early invasion in bladder cancer. Furthermore, p53 anderbB-2 may be important predictors for metastasis.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...